Carmofur

Last updated
Carmofur
Carmofur.svg
Clinical data
Other names1-hexylcarbamoyl-5-fluorouracil, HCFU, N-hexylcarbamoyl-5-fluorouracil, Yamaful, NCGC00095165-01, Hexylcarbamoyl fluorouracil, 61422-45-5, UNII-HA82M3RAB2, CCRIS 2759, C11H16FN3O3, Uracil, 5-fluoro-1-hexylcarbamoyl-, BRN 0888898, HA82M3RAB2, 1(2H)-Pyrimidinecarboxamide, 5-fluoro-N-hexyl-3,4,
AHFS/Drugs.com International Drug Names
Routes of
administration 		Oral
ATC code
Identifiers
  • 5-fluoro-N-hexyl-2,4-dioxo-pyrimidine-1-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.216.315 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C11H16FN3O3
Molar mass 257.265 g·mol−1
3D model (JSmol)
  • CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F
  • InChI=1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18) X mark.svgN
  • Key:AOCCBINRVIKJHY-UHFFFAOYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Carmofur (INN) or HCFU (1-hexylcarbamoyl-5-fluorouracil) is a pyrimidine analogue used as an antineoplastic agent. It is a derivative of fluorouracil, being a lipophilic-masked analog of 5-FU that can be administered orally. [1]

Contents

Biology

Carmofur prodrug is ingested and taken up in the intestine, overcoming the problem of 5-FU degradation by dihydropyrimidine dehydrogenase. Once inside a cell, the carmofur prodrug is converted into 5-FU.

Mechanism of action

The mechanism of action of carmofur prodrug is traditionally thought to be the generation of 5–FU. [2] However, carmofur is a highly potent acid ceramidase (AC) inhibitor. [2] Ceramide influences cancer cell survival, growth and death. [2] Inhibition of AC activity sensitizes tumor cells to the effects of antineoplastic agents and radiation. [2] Carmofur, much more effective than temozolomide, has been reported as the small-molecule drug capable of killing adult and pediatric glioblastomas. [3] [4]

Medicinal uses

Product marketing for carmofur started in 1981. Carmofur has also been used as adjuvant chemotherapy for curatively resected colorectal cancer patients in China, Japan, and Finland for many years. [5] Trials and meta-analyses have confirmed that the drug is effective on patients with this cancer type, extending their survival. [6]

Carmofur has been shown to inhibit the SARS-CoV-2 main protease, and is therefore a promising lead compound to develop new antiviral treatment for COVID-19. [7]

Adverse effects

As fluorouracil, carmofur has been known to induce leukoencephalopathy, characterized by progressive damage to white matter in the brain with stroke-like symptoms. [8] [9] [10]

A clinical trial for small hepatocellular carcinoma was stopped prematurely because 56% of the treated patients had unacceptable side effects. Moreover, the treatment had no survival advantage for stage 1 and 2 cancer patients. [11] This may be a reason why carmofur was never pursued for FDA-approval in the US. [1]

Chemical synthesis

Ozaki et al. have reported a synthesis by treating 5-FU with phosgene and hexylamine. [12] Xiong et al. reported an alternative approach for the synthesis of carmofur . Chemical preparations and structures can be found here. [1]

Related Research Articles

<span class="mw-page-title-main">Cholangiocarcinoma</span> Bile duct adenocarcinoma

Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. Symptoms of cholangiocarcinoma may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever. Light colored stool or dark urine may also occur. Other biliary tract cancers include gallbladder cancer and cancer of the ampulla of Vater.

Fluorouracil, sold under the brand name Adrucil among others, is a cytotoxic chemotherapy medication used to treat cancer. By intravenous injection it is used for treatment of colorectal cancer, oesophageal cancer, stomach cancer, pancreatic cancer, breast cancer, and cervical cancer. As a cream it is used for actinic keratosis, basal cell carcinoma, and skin warts.

<span class="mw-page-title-main">Carboplatin</span> Medication used to treat cancer

Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.

An antimetabolite is a chemical that inhibits the use of a metabolite, which is another chemical that is part of normal metabolism. Such substances are often similar in structure to the metabolite that they interfere with, such as the antifolates that interfere with the use of folic acid; thus, competitive inhibition can occur, and the presence of antimetabolites can have toxic effects on cells, such as halting cell growth and cell division, so these compounds are used in chemotherapy for cancer.

<span class="mw-page-title-main">History of cancer chemotherapy</span>

The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.

<span class="mw-page-title-main">Oxaliplatin</span> Pharmaceutical drug

Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication used to treat colorectal cancer. It is given by injection into a vein.

<span class="mw-page-title-main">Epirubicin</span> Chemical compound

Epirubicin is an anthracycline drug used for chemotherapy. It can be used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin Ebewe elsewhere.

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

Tegafur/uracil is a chemotherapy drug combination used in the treatment of cancer, primarily bowel cancer. It is also called UFT or UFUR.

<span class="mw-page-title-main">ASAH1</span> Protein-coding gene in the species Homo sapiens

The ASAH1 gene encodes in humans the acid ceramidase enzyme.

<span class="mw-page-title-main">FGF19</span> Protein-coding gene in the species Homo sapiens

Fibroblast growth factor 19 is a protein that in humans is encoded by the FGF19 gene. It functions as a hormone, regulating bile acid synthesis, with effects on glucose and lipid metabolism. Reduced synthesis, and blood levels, may be a factor in chronic bile acid diarrhea and in certain metabolic disorders.

<span class="mw-page-title-main">Tegafur</span> Chemical compound

Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU.

<span class="mw-page-title-main">Polysaccharide-K</span>

Polysaccharide-K is a protein-bound polysaccharide isolated from the mycelium of Trametes versicolor.

Wafik El-Deiry is an American physician and cancer researcher who is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Brown University, Director of the Cancer Center at Brown University, and the Director of the Joint Program in Cancer Biology at Brown University and its affiliated hospitals. He was previously deputy director of Translational Research at Fox Chase Cancer Center, where he was also co-Leader of the Molecular Therapeutics Program.

Platinum-based antineoplastic drugs are chemotherapeutic agents used to treat cancer. Their active moieties are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, commonly used drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development. Addition of platinum-based chemotherapy drugs to chemoradiation in women with early cervical cancer seems to improve survival and reduce risk of recurrence.

Antineoplastic resistance, often used interchangeably with chemotherapy resistance, is the resistance of neoplastic (cancerous) cells, or the ability of cancer cells to survive and grow despite anti-cancer therapies. In some cases, cancers can evolve resistance to multiple drugs, called multiple drug resistance.

FOLFIRINOX is a chemotherapy regimen for treatment of advanced pancreatic cancer. It is made up of the following four drugs:

FOLFOXIRI is a chemotherapy regimen for the treatment of advanced colorectal cancer. The role of FOLFOXIRI in colorectal cancer has been reviewed.

Metronomic therapy is a new type of chemotherapy in which anti-cancer drugs are administered in a lower dose than the maximum tolerated dose repetitively over a long period to treat cancers with fewer side effects. Metronomic therapy is shown to affect both tumor microenvironment and tumor cells to achieve its therapeutic effects. Metronomic therapy is also cost-effective as a lower dose is used compared to conventional chemotherapy. The use of metronomic therapy has been extensively investigated and can be advantageous in selected group of patients. Yet, more clinical trials are necessary to generalize the method.

<span class="mw-page-title-main">BOLD-100</span> Experimental cancer drug

BOLD-100, or sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)], is a ruthenium-based anti-cancer therapeutic in clinical development. As of November 2021, BOLD-100 was being tested in a Phase 1b clinical trial in patients with advanced gastrointestinal cancers in combination with the chemotherapy regimen FOLFOX. BOLD-100 is being developed by Bold Therapeutics Inc.

References

  1. 1 2 3 Shelton J, Lu X, Hollenbaugh JA, Cho JH, Amblard F, Schinazi RF (December 2016). "Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs". Chemical Reviews. 116 (23): 14379–14455. doi:10.1021/acs.chemrev.6b00209. PMC   7717319 . PMID   27960273.
  2. 1 2 3 4 Realini N, Solorzano C, Pagliuca C, Pizzirani D, Armirotti A, Luciani R, et al. (Jan 2013). "Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity". Scientific Reports. 3 (1035): 1035. Bibcode:2013NatSR...3E1035R. doi:10.1038/srep01035. PMC   3539145 . PMID   23301156.
  3. ↑ Doan NB, Nguyen HS, Montoure A, Al-Gizawiy MM, Mueller WM, Kurpad S, et al. (April 2017). "Acid ceramidase is a novel drug target for pediatric brain tumors". Oncotarget. 8 (15): 24753–24761. doi:10.18632/oncotarget.15800. PMC   5421885 . PMID   28445970.
  4. ↑ Doan NB, Alhajala H, Al-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, et al. (December 2017). "Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency". Oncotarget. 8 (68): 112662–112674. doi:10.18632/oncotarget.22637. PMC   5762539 . PMID   29348854.
  5. ↑ Sakamoto J, Oba K, Matsui T, Kobayashi M (October 2006). "Efficacy of oral anticancer agents for colorectal cancer". Diseases of the Colon and Rectum. 49 (10 Suppl): S82–S91. doi:10.1007/s10350-006-0601-7. PMID   17106820. S2CID   30655861.
  6. ↑ Sakamoto J, Hamada C, Rahman M, Kodaira S, Ito K, Nakazato H, et al. (September 2005). "An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer". Japanese Journal of Clinical Oncology. 35 (9): 536–544. doi: 10.1093/jjco/hyi147 . PMID   16155120.
  7. ↑ Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu Y, et al. (June 2020). "Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur". Nature Structural & Molecular Biology. 27 (6): 529–532. doi: 10.1038/s41594-020-0440-6 . PMID   32382072.
  8. ↑ Yamada T, Okamura S, Okazaki T, Ushiroyama T, Yanagawa Y, Ueki M, et al. (June 1989). "Leukoencephalopathy following treatment with carmofur: a case report and review of the Japanese literature". Asia-Oceania Journal of Obstetrics and Gynaecology. 15 (2): 161–168. doi:10.1111/j.1447-0756.1989.tb00171.x. PMID   2667512.
  9. ↑ Mizutani T (February 2008). "[Leukoencephalopathy caused by antineoplastic drugs]". Brain and Nerve = Shinkei Kenkyu No Shinpo (in Japanese). 60 (2): 137–141. PMID   18306661.
  10. ↑ Baehring JM, Fulbright RK (May 2008). "Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients". Journal of Neurology, Neurosurgery, and Psychiatry. 79 (5): 535–539. doi:10.1136/jnnp.2007.123737. PMID   17682013. S2CID   38293604.
  11. ↑ Yamamoto M, Arii S, Sugahara K, Tobe T (March 1996). "Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma". The British Journal of Surgery. 83 (3): 336–340. doi: 10.1002/bjs.1800830313 . PMID   8665186. S2CID   28134419.
  12. ↑ Ozaki S, Nagase T, Ahmad S, Tamai H, Hoshi A, Iigo M (1987). "Synthesis and antitumor activity of 1- or 3-(alpha-hetero substituted)alkyl-5-fluorouracil derivatives". Nucleic Acids Symposium Series. 18 (18): 1–4. PMID   3697106.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.